Cargando…

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers

Acquired resistance to epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a critical obstacle in the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). EHD1, a protein of the C-terminal Eps15 homology domain-containing (EHD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaoyuan, Yin, Hang, Zhang, Hongxia, Hu, Jing, Lu, Hailing, Li, Chunhong, Cao, Mengru, Yan, Shi, Cai, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856828/ https://www.ncbi.nlm.nih.gov/pubmed/29549343 http://dx.doi.org/10.1038/s41419-018-0447-7

Ejemplares similares

MALT1 is required for EGFR induced NF-κB activation and contributes to EGFR-driven lung cancer progression
por: Pan, Deng, et al.
Publicado: (2015)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
por: Sueangoen, Natthaporn, et al.
Publicado: (2020)

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer
por: Li, Hongde, et al.
Publicado: (2016)

EHDS are serine phosphoproteins: EHD1 phosphorylation is enhanced by serum stimulation
por: Fichtman, Boris, et al.
Publicado: (2008)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
por: Schöttle, Jakob, et al.
Publicado: (2015)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

EHD2 regulates caveolar dynamics via ATP-driven targeting and oligomerization
por: Morén, Björn, et al.
Publicado: (2012)

A Review on Electrohydrodynamic (EHD) Pump
por: Peng, Yanhong, et al.
Publicado: (2023)

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

The role of PHIRI in the EHDS2
por: Bernal-Delgado, E, et al.
Publicado: (2022)

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
por: Galvani, Elena, et al.
Publicado: (2015)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
por: Jiang, Ye, et al.
Publicado: (2018)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
por: Kibirova, Albina, et al.
Publicado: (2019)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020)

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC
por: Li, Ling, et al.
Publicado: (2017)

Renal Thrombotic Microangiopathy in Mice with Combined Deletion of Endocytic Recycling Regulators EHD3 and EHD4
por: George, Manju, et al.
Publicado: (2011)

A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma
por: Liu, Yuechao, et al.
Publicado: (2022)

Early steps in primary cilium assembly require EHD1- and EHD3-dependent ciliary vesicle formation
por: Lu, Quanlong, et al.
Publicado: (2015)

Differential requirements for the Eps15 homology domain proteins EHD4 and EHD2 in the regulation of mammalian ciliogenesis
por: Jones, Tyler, et al.
Publicado: (2022)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Preparation of active 3D film patches via aligned fiber electrohydrodynamic (EHD) printing
por: Wang, Jun-Chuan, et al.
Publicado: (2017)

Effects of EHD2 interference on migration of esophageal squamous cell carcinoma
por: Li, Mei, et al.
Publicado: (2013)

Spatio-temporal regulation of EGFR signaling by the Eps15 homology domain-containing protein 3 (EHD3)
por: Amessou, Mohamed, et al.
Publicado: (2016)

EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
por: Ma, Lichun, et al.
Publicado: (2015)

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
por: Ayeni, Deborah, et al.
Publicado: (2019)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

Electrohydrodynamic (EHD) drying of the Chinese wolfberry fruits
por: Yang, Maosheng, et al.
Publicado: (2016)

Nanoparticle assembly enabled by EHD-printed monolayers
por: Porter, Benjamin Francis, et al.
Publicado: (2017)

Increased expression of miR‐641 contributes to erlotinib resistance in non‐small‐cell lung cancer cells by targeting NF1
por: Chen, Juan, et al.
Publicado: (2018)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
por: Wang, Debby D., et al.
Publicado: (2015)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen, Kim-Son H, et al.
Publicado: (2012)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells
por: Feng, Jingwen, et al.
Publicado: (2022)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ap744o8g3h56djbq66ed3qppuc